Literature DB >> 19261799

Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.

Nicole Wolter1, Mignon du Plessis, Anne von Gottberg, Linda de Gouveia, Keith P Klugman.   

Abstract

Fluoroquinolones are not indicated for use for the treatment of pneumonia in children; however, non-levofloxacin-susceptible Streptococcus pneumoniae (NLSSP) has emerged in South Africa among children receiving treatment for multidrug-resistant tuberculosis. This study aimed to genotypically characterize NLSSP isolates. Invasive isolates were collected through active national laboratory-based surveillance for invasive pneumococcal disease (IPD) from 2000 through 2006 (n = 19,404). Carriage studies were conducted at two hospitals for patients with tuberculosis in two provinces. Phenotypic characterization was performed by determination of MICs and serotyping. Fluoroquinolone resistance mutations were identified, and clonality was investigated by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing. Twelve non-levofloxacin-susceptible cases of IPD were identified, and all were in children <15 years of age. Ten isolates were serotype 19F and formed two clusters according to their PFGE profiles, antibiogram types, and fluoroquinolone resistance-conferring mutations. All nine carriage isolates from children in hospital A were NLSSP, serotype 19F, were indistinguishable by PFGE, and were related to invasive isolates in cluster 2. Of 26 child carriers in hospital B, 22 (85%) were colonized with NLSSP. The isolates were indistinguishable by PFGE, although they displayed two serotypes, serotypes 19F and 23F. The isolates were related to invasive isolates in cluster 1; however, higher levofloxacin MICs and different fluoroquinolone resistance mutations were suggestive of horizontal gene transfer. A serotype 23F carriage isolate displayed increased fitness compared with the fitness of an otherwise indistinguishable serotype 19F carriage isolate. These data suggest that a low-level non-levofloxacin-susceptible strain transformed into a highly resistant strain under antibiotic pressure and underwent capsular switching in order to have increased fitness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261799      PMCID: PMC2681833          DOI: 10.1128/JCM.02280-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility.

Authors:  Anne von Gottberg; Herbert Ludewick; Sheila Bamber; Chetna Govind; A Willem Sturm; Keith P Klugman
Journal:  Pediatr Infect Dis J       Date:  2003-11       Impact factor: 2.129

2.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae.

Authors:  M C McEllistrem; J E Stout; L H Harrison
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 4.  The role of clonality in the global spread of fluoroquinolone-resistant bacteria.

Authors:  Keith P Klugman
Journal:  Clin Infect Dis       Date:  2003-03-04       Impact factor: 9.079

5.  Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae.

Authors:  R Hakenbeck; N Balmelle; B Weber; C Gardès; W Keck; A de Saizieu
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

Authors:  Lionel A Mandell; Lance R Peterson; Richard Wise; David Hooper; Donald E Low; Urs B Schaad; Keith P Klugman; Patrice Courvalin
Journal:  Clin Infect Dis       Date:  2002-08-20       Impact factor: 9.079

7.  Interspecies recombination occurs frequently in quinolone resistance-determining regions of clinical isolates of Streptococcus pyogenes.

Authors:  Christoph B Duesberg; Surbhi Malhotra-Kumar; Herman Goossens; Lesley McGee; Keith P Klugman; Tobias Welte; Mathias W R Pletz
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

Review 8.  Molecular mechanisms of fluoroquinolone resistance.

Authors:  Feng-Jui Chen; Hsiu-Jung Lo
Journal:  J Microbiol Immunol Infect       Date:  2003-03       Impact factor: 4.399

9.  Quinolone resistance mechanisms in pneumococci.

Authors:  George M Eliopoulos
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

10.  Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001.

Authors:  Pak-Leung Ho; Tak-Lun Que; Susan S Chiu; Raymond W H Yung; Tak-Keung Ng; Dominic N C Tsang; Wing-Hong Seto; Yu-Lung Lau
Journal:  Emerg Infect Dis       Date:  2004-07       Impact factor: 6.883

View more
  8 in total

1.  International pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance.

Authors:  Daniel Rudolf; Nikolay Michaylov; Mark van der Linden; Ludwig Hoy; Keith P Klugman; Tobias Welte; Mathias W Pletz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

2.  Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.

Authors:  Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; V Thamlikitkul; H Wang; T M So; P-R Hsueh; R M Yasin; C C Carlos; P H Van; J Perera
Journal:  Infection       Date:  2012-07-22       Impact factor: 3.553

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Molecular characterization of quinolone resistance-determining regions and their correlation with serotypes and genotypes among Streptococcus pneumoniae isolates in Japan.

Authors:  M Osawa; Y Ito; T Ishida; S Imai; S Ichiyama; M Mishima
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-24       Impact factor: 3.267

6.  Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; T M So; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-06       Impact factor: 3.267

7.  Spread of Streptococcus pneumoniae serotype 8-ST63 multidrug-resistant recombinant Clone, Spain.

Authors:  Carmen Ardanuy; Adela G de la Campa; Ernesto García; Asunción Fenoll; Laura Calatayud; Emilia Cercenado; Emilio Pérez-Trallero; Emilio Bouza; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883

8.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.